



## IN THIS ISSUE

- Protocol Update - BRAVTRAP, UBRAVTR, GUEP, GUVIP2, LYABVD
- Pre-Printed Order Update - GOOVEXT2, GOOVTOP, HNFUFA, HNPE, LYODBEP, LYSNCC, SAVAC
- Patient Educational Materials - Mouth care of cancer patients
- Drug Update - trastuzumab (Herceptin®) eligibility expanded
- Communities Oncology Network - summary of CON Conference in November 1999

FAX request form and IN TOUCH phone list are provided if additional information is needed.

## PROTOCOL UPDATE

Protocol codes for treatments requiring "Undesignated Indication" approval prior to use are prefixed with the letter **U**.

- **INDEX** to BCCA Protocol Summaries revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **BRAVTRAP** - revised (vital signs prior to trastuzumab deleted, HER-2 eligibility changed from 3+ to 2+): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) and paclitaxel (Taxol®) as first-line treatment for recurrent breast cancer refractory to anthracycline adjuvant chemotherapy
- **UBRAVTR** - revised (vital signs prior to trastuzumab deleted): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®)
- **GUEP** - revised (title, contact physician and ondansetron dosing changed, magnesium added to monitoring tests): Etoposide-cisplatin protocol for germ cell cancers
- **GUVIP** - revised (prophylactic antibiotic reinstated): Nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide and mesna
- **LYABVD** - revised (tests, premedications,

filgrastim dose, and precautions added, dose modifications revised): Treatment of Hodgkin's lymphoma with doxorubicin, bleomycin, vinblastine and dacarbazine

## PRE-PRINTED ORDER UPDATE

Vancouver Cancer Centre has prepared the following pre-printed orders for chemotherapy protocol:

- **GOOVEXT2** – deleted: Protocol for visible residual epithelial ovarian cancer
- **GOOVTOP** – Treatment of relapsed or progressive epithelial ovarian, fallopian tube or primary peritoneal cancer using topotecan
- **HNFUFA** – 5-Fluorouracil and leucovorin for recurrent head and neck cancer
- **HNPE** – Intensive cisplatin and etoposide chemotherapy for recurrent and metastatic head and neck cancer
- **LYODBEP** – Treatment of Hodgkin's disease with vincristine, doxorubicin, bleomycin, etoposide and prednisone
- **LYSNCC** – Treatment of Burkitt lymphoma with cyclophosphamide and methotrexate (Day 1 and Day 10 orders)
- **SAVAC** – Adjuvant therapy for patients with newly diagnosed Ewing's sarcoma/peripheral neuroectodermal tumour or rhabdomyosarcoma using vincristine, doxorubicin and cyclophosphamide

## PATIENT EDUCATIONAL MATERIALS

Mouth care of the cancer patient - Cancer patients can experience oral discomfort, possibly coupled with soft and hard tissue breakdown, as a result of cancer or the treatment of cancer. Many of these problems can be minimized or prevented with appropriate measures. However, there are few commonly available authoritative sources from which such information can be obtained. Good prevention of these potential problems can significantly improve the quality of life for those who may be at risk. As well, it can

dramatically reduce the cost of dental treatment and oral care in future years.

The BCCA Department of Dentistry has adopted the use of a number of reference and educational materials concerning mouth care of the cancer patient. These materials have been refined and developed by the National Institutes of Health from materials originally produced by the members of the International Society for Oral Oncology, and the University of Missouri at Kansas City. The materials comprise:

Title	Publication number
"What the Oncology Team Can Do"	#99-4360 (OCCT-2)
"What the Oral Health Team Can Do"	#99-4372 (OCCT-1)
"Chemotherapy and Your Mouth"	#99-4361 (OCCT-6)
"Radiation Treatment and Your Mouth"	#99-4362 (OCCT-5)
"Oncology Reference Guide"	(OCCT-4)
"Oral Care Provider's Reference Guide"	(OCCT-3)
"Three good reasons to see a dentist"	(OCCT-8)
"Sample kit for the oral health professional" includes all patient publications and materials for the oral health professional.	(OCCT-9)
"Sample kit for the oncology professional" includes all patient publications for the oncology professional.	(OCCT-10)

Copies of these materials are available in limited quantities from the BCCA Cancer Information Centre and Library. They are also available at no cost from:

U.S. Department of Health and Human Services,  
National Institutes of Health,  
Attn: OCCT,  
1 NOHIC Way  
Bethesda, Maryland 20892-3500

The web page for this material is found at <http://www.aerie.com/nohicweb/campaign/titlepg.htm>.

### DRUG UPDATE

**Trastuzumab (Herceptin®) eligibility expanded** - the BCCA Breast Tumour Group has sent out a letter to community oncologists regarding the expanded eligibility on trastuzumab use. This agent is currently approved for use with paclitaxel as first-line therapy for metastatic breast cancer who recur within one year after adjuvant anthracycline

chemotherapy (protocol BRAVTRAP). Patient eligibility criteria have now been expanded from +3 to a minimum of +2 HER-2 positivity by immunocytochemistry as determined by the BCCA lab. For further details on trastuzumab treatment indications and HER-2 testing, please refer to the letter from the Breast Tumour Group (available on Fax-Back).

### COMMUNITIES ONCOLOGY NETWORK

**CON Conference November 1999** - An update meeting of the PANDA system was presented at the CON Conference in Richmond, BC, on November 1999. Questions and concerns with the CON Reimbursement Process were discussed at the meeting, including the challenges, drug expenditures and reimbursement turnaround times amongst pharmacy services. As well, there was a presentation on the update to the PANDA system, a Y2K requirement. During the question/answer period, the following issues were discussed:

- Communication of approval and receipt of Class II and Undesignated forms
- Pharmacists completing the Class II forms instead of physicians
- BCCA Pre-Printed Orders as guideline for CON hospitals to develop their own pre-printed orders
- On-line Adjudication
- Temporary Registration Process

The meeting was concluded with a brief discussion on the next steps towards improvements to the reimbursement process and strengthening of the partnerships. Anyone with questions or would like more information on the above issues can contact Francis Hu, CON pharmacist, at (604) 877-6098 ext 2515 or toll-free 1-800-663-3333 local 2515.

### Editorial Review Board

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD  
Sandi Broughton, BA(Econ), MSc  
Jack Chritchley, MD  
Linda Yearwood, MSN  
Lynne Nakashima, PharmD  
Kelly Uyeno, CGA

Gigi Concon (Secretary )

<b>IN TOUCH</b>	<a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 370-8228	Toll-Free 1-(800)-670-3322
Communities Oncology Network	(604) 877-6098 Ext 2744	Toll-Free 1-(800)-663-3333 Ext 2744
Nursing Professional Practice	(604)-877-6098 Ext 2623	Toll-Free 1-(800)-663-3333 Ext 2623
Pharmacy Professional Practice	(604)-877-6098 Ext 2247	Toll-Free 1-(800)-663-3333 Ext 2247
Provincial Systemic Therapy Program	(604)-877-6098 Ext 2247	Toll-Free 1-(800)-663-3333 Ext 2247
Francis Hu, CON Pharmacist	(604)-877-6098 Ext 2515	<a href="mailto:francish@bccancer.bc.ca">francish@bccancer.bc.ca</a>
Mário de Lemos, Update Editor	(604)-877-6098 Ext 2288	<a href="mailto:mdelemos@bccancer.bc.ca">mdelemos@bccancer.bc.ca</a>
Robin O'Brien, Drug Information	(604)-877-6098 Ext 3028	<a href="mailto:robrien@bccancer.bc.ca">robrien@bccancer.bc.ca</a>

## RADIATION CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\vcc\
	H:\everyone\systemic\chemo\Orders\vcc\gyne\goovtop.doc
	H:\everyone\systemic\chemo\Orders\vcc\head&neck\hnfufa.doc
	H:\everyone\systemic\chemo\Orders\vcc\head&neck\hnpe.doc
	H:\everyone\systemic\chemo\Orders\vcc\lymphoma...\lyodbep.doc
	H:\everyone\systemic\chemo\Orders\vcc\lymphoma...\lysncc.doc
	H:\everyone\systemic\chemo\Orders\vcc\sarcoma\savac.doc
Index of Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\VCC\Index.doc
Protocol Summaries	H:\everyone\systemic\chemo\Protocol\breast\bravtrap.doc
	H:\everyone\systemic\chemo\Protocol\breast\ubravtr.doc
	H:\everyone\systemic\chemo\Protocol\gu\guedp.doc
	H:\everyone\systemic\chemo\Protocol\gu\guvip.doc
	H:\everyone\systemic\chemo\Protocol\lymphoma...\lyabvd.doc
Index of Protocol Summaries	H:\everyone\systemic\chemo\Protocol\Index\Index_NT or Index_W6
Reimbursement	H:\everyone\systemic\chemo\Reimburs
Benefit Drug List	H:\everyone\systemic\chemo\Reimburs\Benefit.doc
Class 2 Form	H:\everyone\systemic\chemo\Reimburs\Class2.doc

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at [bulletin@bccancer.bc.ca](mailto:bulletin@bccancer.bc.ca)

## BCCA SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

**FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247**

**OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247**

**PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES**

*I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:*

E-mail (Word 6.0)

@

Fax

(      )

Attn:

**UPDATES** Please  Fax-Back information below:

- |                          |  |
|--------------------------|--|
| <input type="checkbox"/> | All items  |
|                          | Pre-Printed Orders:  |
| <input type="checkbox"/> | GOOVTOP  |
| <input type="checkbox"/> | HNFUFA   |
| <input type="checkbox"/> | HNPE   |
| <input type="checkbox"/> | LYODBEP  |
| <input type="checkbox"/> | LYSNCC (Day 1 and Day 10 orders)   |
| <input type="checkbox"/> | SAVAC (outpatient order)   |
| <input type="checkbox"/> | Index: Pre-Printed Orders  |
|                          | Protocol Summaries:  |
| <input type="checkbox"/> | BRAVTRAP   |
| <input type="checkbox"/> | UBRAVTR  |
| <input type="checkbox"/> | GUEP   |
| <input type="checkbox"/> | GUVIP  |
| <input type="checkbox"/> | LYABVD   |
| <input type="checkbox"/> | Index: Protocol Summaries (February 2000)  |
| <input type="checkbox"/> | Breast Tumour Group letter on trastuzumab (Herceptin®) indications and HER-2 testing |
|                          | Reimbursement  |
| <input type="checkbox"/> | Benefit Drug List (01 Nov 99)  |
| <input type="checkbox"/> | Class 2 Form (01 Nov 99)   |